An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT00359021
First received: July 28, 2006
Last updated: May 6, 2014
Last verified: May 2014
Results First Received: January 29, 2013  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: HIV-1
Intervention: Drug: TMC125

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participants with human immunodeficiency virus – type 1 (HIV-1) infection were enrolled in this study from DUET Study TMC125-C206 or TMC125-C216 and met the definition of virologic failure at Week 24 or later in these studies, or who completed one of the DUET studies after 96 weeks of treatment.

Reporting Groups
  Description
DUET PLACEBO Participants who received Placebo in a previous DUET study and received open-label treatment with 200 mg twice daily etravirine, also known as TMC125 (ETR) and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-naïve participants.
DUET TMC125 Participants who received etravirine, also known as TMC125 (ETR) in a previous DUET study and received open-label treatment with 200 mg twice daily ETR and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-experienced participants.

Participant Flow:   Overall Study
    DUET PLACEBO     DUET TMC125  
STARTED     256     247  
COMPLETED     175     195  
NOT COMPLETED     81     52  
Adverse Event                 26                 8  
Subject Non-Compliant                 1                 2  
Subject Ineligible To Continue The Trial                 1                 0  
Subject Reached A Virologic Endpoint                 45                 32  
Withdrawal by Subject                 2                 9  
Lost to Follow-up                 1                 0  
Not specified                 4                 1  
Pregnancy                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
DUET PLACEBO Participants who received Placebo in a previous DUET study and received open-label treatment with 200 mg twice daily etravirine, also known as TMC125 (ETR) and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-naïve participants.
DUET TMC125 Participants who received etravirine, also known as TMC125 (ETR) in a previous DUET study and received open-label treatment with 200 mg twice daily ETR and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-experienced participants.
Total Total of all reporting groups

Baseline Measures
    DUET PLACEBO     DUET TMC125     Total  
Number of Participants  
[units: participants]
  256     247     503  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     252     245     497  
>=65 years     4     2     6  
Age  
[units: years]
Mean ± Standard Deviation
  46.9  ± 8.28     46.6  ± 7.01     46.7  ± 7.68  
Gender  
[units: participants]
     
Female     27     37     64  
Male     229     210     439  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Number of Participants Experiencing Adverse Events   [ Time Frame: 1 week to 180 weeks, with a median of 62 weeks ]

2.  Secondary:   The Percentage of Participants With Virologic Outcomes Over Time   [ Time Frame: Weeks 24, 48, and 96 ]

3.  Secondary:   Change in Plasma Viral Load Versus Baseline (ie, Mean Change in log10 Plasma Viral Load From Baseline Over Time)   [ Time Frame: Baseline, Week 24, Week 48, and Week 96 ]


  Serious Adverse Events


  Other Adverse Events
  Hide Other Adverse Events

Time Frame 07-Jun-2006 to 24-Jan-2012.
Additional Description All "Serious Adverse Events (SAEs)" emerging during the TMC125-C217 treatment period are reported below; "Other Adverse Events (not including SAEs)" provided below occurred in at least 0.5% of participants. The duration of the TMC125 treatment period ranged per patient from 1 week to 180 weeks, with a median of 62 weeks.

Frequency Threshold
Threshold above which other adverse events are reported   5%  

Reporting Groups
  Description
DUET PLACEBO Participants who received Placebo in a previous DUET study and received open-label treatment with 200 mg twice daily etravirine, also known as TMC125 (ETR) and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-naïve participants.
DUET TMC125 Participants who received etravirine, also known as TMC125 (ETR) in a previous DUET study and received open-label treatment with 200 mg twice daily ETR and 600/100 mg twice daily darunavir (DRV)/low-dose ritonavir (rtv) were referred to as ETR-experienced participants.
All Participants Participants who received placebo or TMC125 in a previous DUET study (DUET Placebo + DUET TMC125).

Other Adverse Events
    DUET PLACEBO     DUET TMC125     All Participants  
Total, other (not including serious) adverse events        
# participants affected / at risk     160/256     137/247     297/503  
Gastrointestinal disorders        
Diarrhoea * 1      
# participants affected / at risk     32/256 (12.50%)     24/247 (9.72%)     56/503 (11.13%)  
Nausea * 1      
# participants affected / at risk     20/256 (7.81%)     15/247 (6.07%)     35/503 (6.96%)  
General disorders        
Injection site nodule * 1      
# participants affected / at risk     14/256 (5.47%)     8/247 (3.24%)     22/503 (4.37%)  
Pyrexia * 1      
# participants affected / at risk     13/256 (5.08%)     6/247 (2.43%)     19/503 (3.78%)  
Infections and infestations        
Bronchitis * 1      
# participants affected / at risk     18/256 (7.03%)     12/247 (4.86%)     30/503 (5.96%)  
Herpes simplex * 1      
# participants affected / at risk     32/256 (12.50%)     17/247 (6.88%)     49/503 (9.74%)  
Influenza * 1      
# participants affected / at risk     18/256 (7.03%)     18/247 (7.29%)     36/503 (7.16%)  
Nasopharyngitis * 1      
# participants affected / at risk     21/256 (8.20%)     15/247 (6.07%)     36/503 (7.16%)  
Oral candidiasis * 1      
# participants affected / at risk     23/256 (8.98%)     14/247 (5.67%)     37/503 (7.36%)  
Sinusitis * 1      
# participants affected / at risk     19/256 (7.42%)     23/247 (9.31%)     42/503 (8.35%)  
Upper respiratory tract infection * 1      
# participants affected / at risk     14/256 (5.47%)     11/247 (4.45%)     25/503 (4.97%)  
Urinary tract infection * 1      
# participants affected / at risk     14/256 (5.47%)     8/247 (3.24%)     22/503 (4.37%)  
Metabolism and nutrition disorders        
Hypertriglyceridaemia * 1      
# participants affected / at risk     12/256 (4.69%)     15/247 (6.07%)     27/503 (5.37%)  
Musculoskeletal and connective tissue disorders        
Arthralgia * 1      
# participants affected / at risk     7/256 (2.73%)     14/247 (5.67%)     21/503 (4.17%)  
Nervous system disorders        
Headache * 1      
# participants affected / at risk     18/256 (7.03%)     10/247 (4.05%)     28/503 (5.57%)  
Psychiatric disorders        
Insomnia * 1      
# participants affected / at risk     13/256 (5.08%)     7/247 (2.83%)     20/503 (3.98%)  
Respiratory, thoracic and mediastinal disorders        
Cough * 1      
# participants affected / at risk     12/256 (4.69%)     14/247 (5.67%)     26/503 (5.17%)  
Skin and subcutaneous tissue disorders        
Rash * 1      
# participants affected / at risk     24/256 (9.38%)     4/247 (1.62%)     28/503 (5.57%)  
* Events were collected by non-systematic assessment
1 Term from vocabulary, MedDRA 9.1



  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information